NO20051658L - Terapeutisk behandling - Google Patents

Terapeutisk behandling

Info

Publication number: NO20051658L
Authority: NO; Norway
Prior art keywords: therapeutic treatment; pharmaceutically acceptable; acceptable salt; disclosed; combination
Prior art date: 2002-10-12

Application number

NO20051658A

Other languages

English (en)

Norwegian (no)

Inventor

Francis Thomas Boyle

Jon Owen Curwen

David William Tonge

Sian Tomiko Taylor

Andrew Mark Hughes

Donna Johnstone

Neil James Gallagher

Ursula Joy Hancox

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-12

Filing date

2005-04-04

Publication date

2005-05-06

2005-04-04 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-05-06 Publication of NO20051658L publication Critical patent/NO20051658L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20051658A 2002-10-12 2005-04-04 Terapeutisk behandling NO20051658L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0223854.1A GB0223854D0 (en)	2002-10-12	2002-10-12	Therapeutic treatment
PCT/GB2003/004347 WO2004035057A1 (fr)	2002-10-12	2003-10-07	Traitement therapeutique

Publications (1)

Publication Number	Publication Date
NO20051658L true NO20051658L (no)	2005-05-06

Family

ID=9945876

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20051658A NO20051658L (no)	2002-10-12	2005-04-04	Terapeutisk behandling

Country Status (29)

Country	Link
US (1)	US20060122180A1 (fr)
EP (1)	EP1553950B1 (fr)
JP (1)	JP2006510605A (fr)
KR (1)	KR20050056238A (fr)
CN (1)	CN100342853C (fr)
AR (1)	AR041595A1 (fr)
AT (1)	ATE369136T1 (fr)
AU (1)	AU2003269259B2 (fr)
BR (1)	BR0315140A (fr)
CA (1)	CA2501959A1 (fr)
CY (1)	CY1107605T1 (fr)
DE (1)	DE60315490T2 (fr)
DK (1)	DK1553950T3 (fr)
ES (1)	ES2289316T3 (fr)
GB (1)	GB0223854D0 (fr)
IS (1)	IS2473B (fr)
MX (1)	MXPA05003808A (fr)
MY (1)	MY135441A (fr)
NO (1)	NO20051658L (fr)
NZ (1)	NZ539137A (fr)
PL (1)	PL375584A1 (fr)
PT (1)	PT1553950E (fr)
RU (1)	RU2005114487A (fr)
SA (1)	SA04240502B1 (fr)
TW (1)	TW200412971A (fr)
UA (1)	UA82492C2 (fr)
UY (1)	UY28017A1 (fr)
WO (1)	WO2004035057A1 (fr)
ZA (1)	ZA200502874B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0218526D0 (en) *	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0219660D0 (en)	2002-08-23	2002-10-02	Astrazeneca Ab	Therapeutic use
WO2004100991A1 (fr) *	2003-05-15	2004-11-25	Universite Catholique De Louvain	Utilisation d'antagonistes de l'endotheline-1 pour ameliorer le traitement des cancers
GB0320806D0 (en) *	2003-09-05	2003-10-08	Astrazeneca Ab	Therapeutic treatment
GB0403744D0 (en)	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
GB0425854D0 (en) *	2004-11-25	2004-12-29	Astrazeneca Ab	Therapeutic treatment
JP2009530279A (ja) *	2006-03-13	2009-08-27	エンサイシブ・ファーマシューティカルズ・インコーポレイテッド	Ｎ−（４−クロロ−３−メチル−５−イソキサゾリル）２−［２−メチル−４，５−（メチレンジオキシ）フェニルアセチル］チオフェン−３−スルホンアミド、ナトリウム塩の多形
EA201000545A1 (ru) *	2007-10-12	2010-10-29	Астразенека Аб	Композиция зиботентана, содержащая маннит и/или микрокристаллическую целлюлозу
MX2012001562A (es) *	2009-08-10	2013-01-29	Univ Texas	Tratamiento de astrocitos-celulas de tumor con inhibidores de receptores de endotelina.
WO2017024032A2 (fr)	2015-08-03	2017-02-09	Enb Therapeutics, Llc	Compositions et procédés pour traiter des cancers associés à l'activation d'etbr
MX2020007293A (es)	2018-01-12	2021-01-08	Enb Therapeutics Inc	Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
WO2021011925A1 (fr) *	2019-07-17	2021-01-21	Enb Therapeutics, Inc.	Traitement des cancers urothélial et rénal par l'utilisation d'antagonistes du récepteur de l'endothéline b
AR126178A1 (es)	2021-06-22	2023-09-27	Alchemedicine Inc	Compuesto, antagonista del receptor de endotelina a y composición farmacéutica

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5464853A (en) *	1993-05-20	1995-11-07	Immunopharmaceutics, Inc.	N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) *	1993-05-20	1996-05-07	Immunopharmaceutics, Inc.	N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9300059D0 (en) *	1992-01-20	1993-03-03	Zeneca Ltd	Quinazoline derivatives
US6063911A (en) *	1993-12-01	2000-05-16	Marine Polymer Technologies, Inc.	Methods and compositions for treatment of cell proliferative disorders
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
UA58494C2 (uk) *	1995-06-07	2003-08-15	Зенека Лімітед	Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
US5780435A (en) *	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
CN1298396A (zh) *	1998-04-29	2001-06-06	Osi药物公司	N－(乙炔苯氨基)－6,7－双(2－甲氧基乙氧基)－4－喹唑啉胺甲磺酸盐无水物和一水合物
US6355678B1 (en) *	1998-06-29	2002-03-12	Parker Hughes Institute	Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
GB0008368D0 (en) *	2000-04-06	2000-05-24	Astrazeneca Ab	Combination product
US20020055457A1 (en) *	2000-08-07	2002-05-09	Janus Todd J.	Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) *	2001-04-11	2003-05-15	Amitabh Singh	Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
DE10155076A1 (de) *	2001-11-09	2003-05-22	Merck Patent Gmbh	Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen

2002
- 2002-10-12 GB GBGB0223854.1A patent/GB0223854D0/en not_active Ceased
2003
- 2003-07-10 UA UAA200504329A patent/UA82492C2/uk unknown
- 2003-10-07 WO PCT/GB2003/004347 patent/WO2004035057A1/fr not_active Ceased
- 2003-10-07 CN CNB2003801013102A patent/CN100342853C/zh not_active Expired - Fee Related
- 2003-10-07 BR BR0315140-9A patent/BR0315140A/pt not_active IP Right Cessation
- 2003-10-07 AT AT03751038T patent/ATE369136T1/de active
- 2003-10-07 US US10/530,794 patent/US20060122180A1/en not_active Abandoned
- 2003-10-07 NZ NZ539137A patent/NZ539137A/en not_active IP Right Cessation
- 2003-10-07 RU RU2005114487/15A patent/RU2005114487A/ru unknown
- 2003-10-07 KR KR1020057006232A patent/KR20050056238A/ko not_active Ceased
- 2003-10-07 PL PL03375584A patent/PL375584A1/xx not_active Application Discontinuation
- 2003-10-07 JP JP2004544431A patent/JP2006510605A/ja active Pending
- 2003-10-07 EP EP03751038A patent/EP1553950B1/fr not_active Expired - Lifetime
- 2003-10-07 CA CA002501959A patent/CA2501959A1/fr not_active Abandoned
- 2003-10-07 DK DK03751038T patent/DK1553950T3/da active
- 2003-10-07 DE DE60315490T patent/DE60315490T2/de not_active Expired - Lifetime
- 2003-10-07 PT PT03751038T patent/PT1553950E/pt unknown
- 2003-10-07 MX MXPA05003808A patent/MXPA05003808A/es active IP Right Grant
- 2003-10-07 ES ES03751038T patent/ES2289316T3/es not_active Expired - Lifetime
- 2003-10-07 AU AU2003269259A patent/AU2003269259B2/en not_active Ceased
- 2003-10-09 TW TW092128113A patent/TW200412971A/zh unknown
- 2003-10-10 AR ARP030103717A patent/AR041595A1/es unknown
- 2003-10-10 MY MYPI20033877A patent/MY135441A/en unknown
- 2003-10-13 UY UY28017A patent/UY28017A1/es not_active Application Discontinuation
2004
- 2004-02-18 SA SA04240502A patent/SA04240502B1/ar unknown
2005
- 2005-04-04 NO NO20051658A patent/NO20051658L/no not_active Application Discontinuation
- 2005-04-08 ZA ZA200502874A patent/ZA200502874B/en unknown
- 2005-04-26 IS IS7825A patent/IS2473B/is unknown
2007
- 2007-10-08 CY CY20071101275T patent/CY1107605T1/el unknown

Also Published As

Publication number	Publication date
TW200412971A (en)	2004-08-01
GB0223854D0 (en)	2002-11-20
UY28017A1 (es)	2004-04-30
WO2004035057A1 (fr)	2004-04-29
IS7825A (is)	2005-04-26
EP1553950B1 (fr)	2007-08-08
MY135441A (en)	2008-04-30
ZA200502874B (en)	2006-02-22
ATE369136T1 (de)	2007-08-15
AU2003269259A1 (en)	2004-05-04
CY1107605T1 (el)	2013-03-13
UA82492C2 (uk)	2008-04-25
JP2006510605A (ja)	2006-03-30
RU2005114487A (ru)	2006-02-10
ES2289316T3 (es)	2008-02-01
DK1553950T3 (da)	2007-10-15
US20060122180A1 (en)	2006-06-08
DE60315490T2 (de)	2008-05-08
DE60315490D1 (de)	2007-09-20
NZ539137A (en)	2008-01-31
CN100342853C (zh)	2007-10-17
MXPA05003808A (es)	2005-06-08
AU2003269259B2 (en)	2007-03-15
BR0315140A (pt)	2005-08-16
EP1553950A1 (fr)	2005-07-20
CN1703224A (zh)	2005-11-30
IS2473B (is)	2008-12-15
CA2501959A1 (fr)	2004-04-29
PT1553950E (pt)	2007-09-26
PL375584A1 (en)	2005-11-28
AR041595A1 (es)	2005-05-26
HK1078784A1 (en)	2006-03-24
SA04240502B1 (ar)	2008-09-14
KR20050056238A (ko)	2005-06-14

Publication	Publication Date	Title
CY1107605T1 (el)	2013-03-13	Θεραπευτικη αγωγη
CY1109119T1 (el)	2014-07-02	Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης που περιλαμβανουν λαμοτριγινη
NO2013007I1 (no)	2013-04-29	Dapagliflozin og farmasøytisk akseptable salter derav
NO20052512L (no)	2005-05-25	Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
NO20030596L (no)	2003-04-01	Benzimidazolderivater, deres fremstilling og terapeutiske anvendelse
DE69814394D1 (de)	2003-06-12	Verwendung von levobupivacain
DK1513835T3 (da)	2006-12-27	Piperazinylacylpiperidinderivater, fremstilling og terapeutisk anvendelse heraf
IS2259B (is)	2007-06-15	Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 undireiningunni
EP1570270A4 (fr)	2010-09-22	Bioconjugues therapeutiques
DK1525193T3 (da)	2008-04-28	Acylaminothiazolderivater, deres fremstilling og deres terapeutiske anvendelse
MY137620A (en)	2009-02-27	Therapeutic treatment
NO20051892L (no)	2005-06-17	Ny forbindelse
DK1417189T3 (da)	2006-05-08	Acylaminothiazolderivater, fremstilling og terapeutisk anvendelse heraf
CY1109001T1 (el)	2014-07-02	Οι καππα-οπιοιδεις αγωνιστες στη θεραπεια των παθησεων της κυστης
NO20051893L (no)	2005-06-17	Ny forbindelse
DK1556382T3 (da)	2008-10-06	3-Phenylpyridoindolderivater, fremstilling og terapeutisk anvendelse deraf
AR032422A1 (es)	2003-11-05	Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
DE60305053D1 (de)	2006-06-08	Pyrimidinderivate als selektive cox-2-inhibitoren
NZ535611A (en)	2006-03-31	Pharmaceutical composition of a PDE4 or a PDE3/4 inhibitor and a histamine receptor antagonist
MY136976A (en)	2008-12-31	Novel use of (r)-(-)-2-[5-(4- flourophenyl) -3-pyridylmethylaminomethyl]- chromane and its physiologically acceptable salts
IS2487B (is)	2008-12-15	Asýloxýpýrrólidín afleiður, framleiðsla og meðferðarnotkun þar á
AR038208A1 (es)	2005-01-05	Composicion farmaceutica dispersable oralmente de mitiglinida
NO20022482D0 (no)	2002-05-24	2-arylkinolinderivater, fremgangsmåte og terapeutisk anvendelse derav
NO20023003L (no)	2002-06-21	Benzofenon-glykopyranosider, samt fremstilling og terapeutisk anvendelse
NO993546L (no)	1999-09-21	1,4-dihydropyridinderivater og deres anvendelse i terapi

Legal Events

Date	Code	Title	Description
2012-06-04	FC2A	Withdrawal, rejection or dismissal of laid open patent application